R101
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.620
- ALLOGRAFT_REJECTION+0.510
- COAGULATION+0.480
- IL6_JAK_STAT3_SIGNALING+0.460
- ANGIOGENESIS+0.450
- INFLAMMATORY_RESPONSE+0.440
- INTERFERON_ALPHA_RESPONSE+0.440
- INTERFERON_GAMMA_RESPONSE+0.430
- APICAL_SURFACE+0.410
- KRAS_SIGNALING_DN+0.400
Top 10 suppressed
- PROTEIN_SECRETION-0.480
- OXIDATIVE_PHOSPHORYLATION-0.440
- MYC_TARGETS_V1-0.400
- MITOTIC_SPINDLE-0.330
- ANDROGEN_RESPONSE-0.320
- UNFOLDED_PROTEIN_RESPONSE-0.310
- FATTY_ACID_METABOLISM-0.300
- DNA_REPAIR-0.270
- G2M_CHECKPOINT-0.260
- PI3K_AKT_MTOR_SIGNALING-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD029_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.946 |
| 2 | R426 | — | — | 0.928 |
| 3 | MDT-AP-1125 | Med | Medulloblastoma | 0.926 |
| 4 | MNG133 | — | — | 0.924 |
| 5 | SJEPD001535_R2.RNA-Seq | EPN | Posterior Fossa EPN | 0.924 |
| 6 | MNG1166 | — | — | 0.920 |
| 7 | BS_B0SVFK4P | pleomorphic xanthoastrocytoma(PXA) | — | 0.916 |
| 8 | SRR818469 | GTEX | — | 0.916 |
| 9 | BS_ZTWGFWTX | pilocytic astrocytoma | — | 0.914 |
| 10 | GSM5359443 | — | — | 0.912 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.620 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.510 | Idelalisib | — uncovered |
| COAGULATION | 0.480 | Binimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.460 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.450 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.440 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.440 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.430 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.410 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.400 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.390 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.360 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.320 | Inavolisib | — uncovered |
| COMPLEMENT | 0.310 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.270 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.260 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.250 | Cobimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.240 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.180 | Inavolisib | — uncovered |
| APOPTOSIS | 0.170 | Idelalisib | — uncovered |